Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$27.42 +3.8%	$27.10	$20.84 ▼ $37.49	$2.29B	1.91	1.20 million shs	4.30 million shs
CBAY CymaBay Therapeutics	$32.48	$32.44	$7.26 ▼ $32.50	$3.73B	0.32	4.11 million shs	73 shs
CRSP CRISPR Therapeutics	$43.49 +2.6%	$43.02	$36.52 ▼ $76.86	$3.73B	1.77	2.26 million shs	1.40 million shs
GILD Gilead Sciences	$113.99 -0.4%	$100.99	$62.07 ▼ $119.96	$141.96B	0.21	8.25 million shs	8.07 million shs
IBRX ImmunityBio	$2.87 +1.8%	$3.07	$2.28 ▼ $10.53	$2.45B	0.82	6.21 million shs	3.43 million shs
MDGL Madrigal Pharmaceuticals	$327.31 -2.4%	$325.79	$189.00 ▼ $377.46	$7.23B	-0.41	442,307 shs	577,730 shs
NTLA Intellia Therapeutics	$9.62 +3.4%	$10.48	$8.30 ▼ $28.88	$995.83M	1.97	3.32 million shs	1.62 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	+3.79%	+5.02%	+3.20%	-2.28%	-23.41%
CBAY CymaBay Therapeutics	0.00%	0.00%	0.00%	0.00%	+0.12%
CRSP CRISPR Therapeutics	+2.64%	-0.80%	+10.35%	-4.21%	-42.24%
GILD Gilead Sciences	-0.38%	-1.26%	+19.39%	+23.39%	+51.82%
IBRX ImmunityBio	+1.77%	-6.21%	-15.34%	-5.59%	-43.17%
MDGL Madrigal Pharmaceuticals	-2.41%	-5.75%	-3.04%	+8.21%	+24.61%
NTLA Intellia Therapeutics	+3.44%	+2.78%	+0.42%	-29.06%	-65.37%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BEAM Beam Therapeutics	3.1206 of 5 stars	4.5	1.0	0.0	0.0	2.5	2.5	0.6
CBAY CymaBay Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	3.3425 of 5 stars	4.2	1.0	0.0	0.0	3.3	3.3	0.6
GILD Gilead Sciences	4.4129 of 5 stars	2.4	3.0	1.7	4.1	2.9	2.5	1.9
IBRX ImmunityBio	2.0527 of 5 stars	3.5	1.0	0.0	0.0	2.5	1.7	0.6
MDGL Madrigal Pharmaceuticals	3.9495 of 5 stars	2.4	2.0	0.0	4.6	2.7	4.2	0.6
NTLA Intellia Therapeutics	4.4592 of 5 stars	4.3	1.0	0.0	4.7	1.8	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	3.00	Buy	$50.82	85.33% Upside
CBAY CymaBay Therapeutics	0.00	N/A	N/A	N/A
CRSP CRISPR Therapeutics	2.48	Hold	$73.11	68.10% Upside
GILD Gilead Sciences	2.72	Moderate Buy	$104.52	-8.31% Downside
IBRX ImmunityBio	3.00	Buy	$12.19	324.65% Upside
MDGL Madrigal Pharmaceuticals	2.85	Moderate Buy	$375.75	14.80% Upside
NTLA Intellia Therapeutics	2.63	Moderate Buy	$37.56	290.39% Upside

Current Analyst Ratings Breakdown

Latest MDGL, BEAM, IBRX, CBAY, GILD, CRSP, and NTLA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/12/2025	BEAM Beam Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/11/2025	GILD Gilead Sciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$123.00 ➝ $130.00
3/10/2025	BEAM Beam Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$34.00
3/10/2025	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
3/10/2025	BEAM Beam Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$57.00
3/10/2025	BEAM Beam Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sector Perform ➝ Sector Outperform	$40.00
3/6/2025	IBRX ImmunityBio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
3/5/2025	GILD Gilead Sciences	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$116.00 ➝ $126.00
3/5/2025	GILD Gilead Sciences	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$120.00 ➝ $140.00
3/5/2025	NTLA Intellia Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$30.00
3/4/2025	GILD Gilead Sciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$115.00 ➝ $132.00

(Data available from 3/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$63.52M	36.13	N/A	N/A	$12.04 per share	2.28
CBAY CymaBay Therapeutics	$31.07M	119.92	N/A	N/A	$2.58 per share	12.59
CRSP CRISPR Therapeutics	$35M	106.58	N/A	N/A	$22.52 per share	1.93
GILD Gilead Sciences	$28.75B	4.94	$9.00 per share	12.66	$15.44 per share	7.38
IBRX ImmunityBio	$14.75M	166.12	N/A	N/A	($0.88) per share	-3.26
MDGL Madrigal Pharmaceuticals	$180.13M	40.12	N/A	N/A	$20.53 per share	15.94
NTLA Intellia Therapeutics	$57.88M	17.21	N/A	N/A	$11.73 per share	0.82

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$132.53M	-$4.58	N/A	N/A	N/A	-41.07%	-16.22%	-10.94%	5/6/2025 (Estimated)
CBAY CymaBay Therapeutics	-$105.37M	-$0.97	N/A	N/A	N/A	N/A	-50.72%	-31.04%	N/A
CRSP CRISPR Therapeutics	-$366.25M	-$4.37	N/A	N/A	N/A	-981.54%	-18.46%	-15.79%	5/14/2025 (Estimated)
GILD Gilead Sciences	$480M	$0.37	308.08	14.06	0.71	1.67%	31.63%	10.38%	4/24/2025 (Estimated)
IBRX ImmunityBio	-$583.20M	-$0.63	N/A	N/A	N/A	-8,016.83%	N/A	-110.02%	3/18/2025 (Estimated)
MDGL Madrigal Pharmaceuticals	-$373.63M	-$22.11	N/A	N/A	N/A	N/A	-71.78%	-53.25%	5/6/2025 (Estimated)
NTLA Intellia Therapeutics	-$481.19M	-$5.25	N/A	N/A	N/A	N/A	-49.34%	-40.27%	5/8/2025 (Estimated)

Latest MDGL, BEAM, IBRX, CBAY, GILD, CRSP, and NTLA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
3/18/2025	N/A	IBRX ImmunityBio	-$0.26	N/A	N/A	N/A	$9.51 million	N/A
3/3/2025	Q4 2024	IBRX ImmunityBio	-$0.26	-$0.15	+$0.11	-$0.09	$8.74 million	$7.55 million
2/26/2025	Q4 2024	MDGL Madrigal Pharmaceuticals	-$4.32	-$2.71	+$1.61	-$2.71	$97.81 million	$103.32 million
2/25/2025	Q4 2024	BEAM Beam Therapeutics	-$1.25	-$1.09	+$0.16	-$1.09	$16.47 million	$30.00 million
2/11/2025	Q4 2024	CRSP CRISPR Therapeutics	-$1.15	-$0.44	+$0.71	-$0.44	N/A	N/A
2/11/2025	Q4 2024	GILD Gilead Sciences	$1.67	$1.90	+$0.23	$1.42	$7.15 billion	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	$0.90	3.28%	N/A	N/A	N/A
CBAY CymaBay Therapeutics	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
GILD Gilead Sciences	$3.16	2.77%	+2.74%	854.05%	N/A
IBRX ImmunityBio	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NTLA Intellia Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest MDGL, BEAM, IBRX, CBAY, GILD, CRSP, and NTLA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/5/2025	GILD Gilead Sciences	quarterly	$0.79	3%	3/14/2025	3/14/2025	3/28/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	N/A	5.69	5.69
CBAY CymaBay Therapeutics	N/A	10.96	10.96
CRSP CRISPR Therapeutics	N/A	22.07	22.07
GILD Gilead Sciences	1.24	1.50	1.20
IBRX ImmunityBio	N/A	2.68	2.64
MDGL Madrigal Pharmaceuticals	0.15	5.98	5.93
NTLA Intellia Therapeutics	N/A	6.73	6.73

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
CBAY CymaBay Therapeutics	95.03%
CRSP CRISPR Therapeutics	69.20%
GILD Gilead Sciences	83.67%
IBRX ImmunityBio	8.58%
MDGL Madrigal Pharmaceuticals	98.50%
NTLA Intellia Therapeutics	88.77%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	4.20%
CBAY CymaBay Therapeutics	7.00%
CRSP CRISPR Therapeutics	4.10%
GILD Gilead Sciences	0.16%
IBRX ImmunityBio	83.40%
MDGL Madrigal Pharmaceuticals	22.80%
NTLA Intellia Therapeutics	3.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	83.69 million	79.33 million	Optionable
CBAY CymaBay Therapeutics	101	114.72 million	106.69 million	Optionable
CRSP CRISPR Therapeutics	473	85.77 million	82.26 million	Optionable
GILD Gilead Sciences	18,000	1.25 billion	1.24 billion	Optionable
IBRX ImmunityBio	590	853.44 million	115.67 million	Optionable
MDGL Madrigal Pharmaceuticals	90	22.08 million	16.84 million	Optionable
NTLA Intellia Therapeutics	600	103.52 million	98.59 million	Optionable

MDGL, BEAM, IBRX, CBAY, GILD, CRSP, and NTLA Headlines

Recent News About These Companies

Intellia Therapeutics (NASDAQ:NTLA) Stock Price Down 6.7% - Time to Sell?

March 12 at 5:13 PM | marketbeat.com

Shareholders of Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights – NTLA

March 12 at 4:30 PM | accessnewswire.com

Shareholders of Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights - NTLA

March 12 at 4:15 PM | accessnewswire.com

NTLA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Intellia Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

March 12 at 4:00 PM | globenewswire.com

Shareholders that lost money on Intellia Therapeutics, Inc.(NTLA) should contact Levi & Korsinsky about pending Class Action - NTLA

March 12 at 7:25 AM | accessnewswire.com

NTLA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Intellia Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!

March 12 at 7:00 AM | accessnewswire.com

Shareholders that lost money on Intellia Therapeutics, Inc.(NTLA) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More

March 12 at 5:45 AM | prnewswire.com

Intellia Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights – NTLA

March 11 at 9:30 PM | accessnewswire.com

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA

March 11 at 9:15 PM | accessnewswire.com

Investors in Intellia Therapeutics, Inc. Should Contact Levi & Korsinsky Before April 14, 2025 to Discuss Your Rights – NTLA

March 11 at 7:45 PM | accessnewswire.com

Intellia Therapeutics, Inc. (NTLA) Barclays 27th Annual Global Healthcare Conference (Transcript)

March 11 at 6:31 PM | seekingalpha.com

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Intellia Therapeutics, Inc of Class Action Lawsuit and Upcoming Deadlines - NTLA

March 11 at 1:41 PM | prnewswire.com

Levi & Korsinsky Notifies Shareholders of Intellia Therapeutics, Inc. (NTLA) of a Class Action Lawsuit and an Upcoming Deadline

March 11 at 10:30 AM | accessnewswire.com

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Intellia Therapeutics

March 11 at 10:02 AM | globenewswire.com

NTLA LAWSUIT ALERT: Levi & Korsinsky Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

March 11 at 7:30 AM | accessnewswire.com

NTLA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Intellia Therapeutics, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit!

March 11 at 7:00 AM | accessnewswire.com

Regeneron Pharmaceuticals Inc. Buys Shares of 3,702,995 Intellia Therapeutics, Inc. (NASDAQ:NTLA)

March 11 at 6:31 AM | marketbeat.com

Intellia Therapeutics, Inc. (NTLA) Leerink 2025 Global Biopharma Conference (Transcript)

March 10 at 6:30 PM | seekingalpha.com

Shareholders that Lost Money on Intellia Therapeutics, Inc. (NTLA) Should Contact Levi & Korsinsky about Pending Class Action - NTLA

March 10 at 6:30 PM | accessnewswire.com

Levi & Korsinsky Notifies Intellia Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - NTLA

March 10 at 4:30 PM | accessnewswire.com

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Intellia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - NTLA

March 10 at 4:04 PM | accessnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Price Targets on NVIDIA Rise in Front of Earnings
By Sarah Horvath | February 24, 2025
View Price Targets on NVIDIA Rise in Front of Earnings
Warren Buffett Swaps VOO for This Reliable Dividend Stock
By Sarah Horvath | March 7, 2025
View Warren Buffett Swaps VOO for This Reliable Dividend Stock
NVIDIA’s Hidden AI Play: The Truth Behind Its WeRide Investment
By Gabriel Osorio-Mazilli | February 14, 2025
View NVIDIA’s Hidden AI Play: The Truth Behind Its WeRide Investment
Archer Aviation Stock Skids: Mistaking Progress for Bad News?
By Chris Markoch | February 24, 2025
View Archer Aviation Stock Skids: Mistaking Progress for Bad News?
Gilead Sciences: 4 Reasons This Stock Has Much More To Rise
By Jea Yu | February 22, 2025
View Gilead Sciences: 4 Reasons This Stock Has Much More To Rise

MDGL, BEAM, IBRX, CBAY, GILD, CRSP, and NTLA Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$27.42 +1.00 (+3.79%)

Closing price 03/12/2025 04:00 PM Eastern

Extended Trading

$27.58 +0.16 (+0.58%)

As of 03/12/2025 07:05 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

CymaBay Therapeutics NASDAQ:CBAY

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California.

CRISPR Therapeutics NASDAQ:CRSP

$43.49 +1.12 (+2.64%)

Closing price 03/12/2025 04:00 PM Eastern

Extended Trading

$43.21 -0.28 (-0.65%)

As of 03/12/2025 08:00 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Gilead Sciences NASDAQ:GILD

$113.99 -0.44 (-0.38%)

Closing price 03/12/2025 04:00 PM Eastern

Extended Trading

$113.38 -0.61 (-0.54%)

As of 03/12/2025 07:42 PM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

ImmunityBio NASDAQ:IBRX

$2.87 +0.05 (+1.77%)

Closing price 03/12/2025 04:00 PM Eastern

Extended Trading

$2.85 -0.02 (-0.70%)

As of 03/12/2025 07:37 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Madrigal Pharmaceuticals NASDAQ:MDGL

$327.31 -8.08 (-2.41%)

Closing price 03/12/2025 04:00 PM Eastern

Extended Trading

$327.46 +0.15 (+0.05%)

As of 03/12/2025 07:59 PM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Intellia Therapeutics NASDAQ:NTLA

$9.62 +0.32 (+3.44%)

Closing price 03/12/2025 04:00 PM Eastern

Extended Trading

$9.64 +0.02 (+0.16%)

As of 03/12/2025 07:36 PM Eastern

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare MarketRank™

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MDGL, BEAM, IBRX, CBAY, GILD, CRSP, and NTLA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MDGL, BEAM, IBRX, CBAY, GILD, CRSP, and NTLA Earnings

Compare Dividends

Latest MDGL, BEAM, IBRX, CBAY, GILD, CRSP, and NTLA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MDGL, BEAM, IBRX, CBAY, GILD, CRSP, and NTLA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

MDGL, BEAM, IBRX, CBAY, GILD, CRSP, and NTLA Company Descriptions

Beam Therapeutics NASDAQ:BEAM

CymaBay Therapeutics NASDAQ:CBAY

CRISPR Therapeutics NASDAQ:CRSP

Gilead Sciences NASDAQ:GILD

ImmunityBio NASDAQ:IBRX

Madrigal Pharmaceuticals NASDAQ:MDGL

Intellia Therapeutics NASDAQ:NTLA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools